Mirion Technologies, Inc. · NYSE:MIR

Mirion Technologies — CJS Securities 23rd Annual New Ideas for the New Year Conference 2023

11 slides from Mirion Technologies's conference presentation, Jan 11, 2023

  1. Slide 1: CJS Securities 23rd Annual New Ideas for the New Year Conference

    CJS Securities 23rd Annual New Ideas for the New Year Conference January 11, 2023 Thomas Logan (CEO) & Brian Schopfer (CFO) The Energy of Innovation © 2022 Mirion Technologies. All rights reserved.

  2. Slide 2: Disclaimer

    Disclaimer Forward-Looking Statements This presentation and the accompanying oral commentary contain forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Words such as “anticipate,” “believe,” “continue,” “could,” “estimate”, “expect”, “hop

  3. Slide 3: Mission & Vision

    Mission & Vision To harness our unrivaled knowledge of ionizing radiation for the greater good of humanity Ensuring Advancing the Worker Health Clean Energy Safety is at the core of our solutions, Mirion… Transition & Safety  Enables safer production of nuclear power, supporting global energy produ

  4. Slide 4: Investment Thesis

    Investment Thesis Recurring revenue profile Technology-based competitive advantage Leadership position in 15 of 18 product categories Diverse product portfolio with high barriers to entry Proven M&A execution and strong pipeline Resilient platform – minimal variability to economic cycles Proven inno

  5. Slide 5: Industrial Segment Overview

    NucMed Dosimetry 8% Industrial Segment Overview 9% Nuclear 38% % of RT QA 17% CY21 Revenue 11% 17% Labs Nuclear Power Defense & Diversified  Essential for safety of personnel and materials from radiation and Key Customer Groups ensuring effective operation of the plant and core  Mirion products us

  6. Slide 6: Nuclear Power Trends and Outlook

    NucMed Dosimetry 8% Nuclear Power Trends and Outlook 9% Nuclear 38% % of RT QA 17% CY21 Revenue 11% 17% Nuclear Power | Mirion services all stages of a plant’s lifecycle; solutions are key to the Labs Defense & Diversified safety of personnel and materials from radiation and ensuring effective opera

  7. Slide 7: Labs, Defense and Diversified Outlook

    NucMed Dosimetry 8% Labs, Defense and Diversified Outlook 9% Nuclear % of 38% RT QA 17% CY21 Revenue 11% 17% Labs Defense & Diversified Labs & Research Defense & Diversified Industrials • Mirion maintains large, defensible market position • Mirion services 19 of the NATO armies • Growing nuclear res

  8. Slide 8: Medical Segment Overview

    NucMed Dosimetry 8% Medical Segment Overview 9% Nuclear 38% RT QA 17% 11% 17% Labs Radiation Therapy Quality Assurance (RT QA) Defense & Diversified  Products are used for calibration and measuring the shape and intensity of radiation treatments for quality assurance  Radiation treatment prescribe

  9. Slide 9: Medical Positioning & Outlook

    Medical Positioning & Outlook 1 Global Population Forecast (in billions) • Market is large and fragmented 9.7 Large Global • Market is global as medical needs are not linked to a 10.0 Market specific geography 8.0 • Developing nations seeking 1st world quality healthcare 6.0 2 4.0 • Technological /

  10. Slide 10: Current priorities and takeaways

    Current priorities and takeaways  Primary focus is delivering core business performance  End markets remain robust  Order momentum and Industrial backlog coverage establish strong foundation for 2023  Assertive price actions continue across the enterprise  We have made a strategic investment in

  11. Slide 11: Q&A Session

    Q&A Session Tom Logan, Chief Executive Officer Brian Schopfer, Chief Financial Officer The Energy of Innovation © 2022 Mirion Technologies. All rights reserved.

Mirion Technologies — CJS Securities 23rd Annual New Ideas for the New Year Conference 2023 on 6ix